Version 1
: Received: 1 September 2019 / Approved: 2 September 2019 / Online: 2 September 2019 (16:34:22 CEST)
How to cite:
Gnoni, A.; Brunetti, O.; Longo, V.; Calabrese, A.; Argentiero, A.; Solimando, A.G.; Licchetta, A. Immune System and Bone Microenvironment: Rationale for Targeted Cancer Therapies. Preprints2019, 2019090026. https://doi.org/10.20944/preprints201909.0026.v1
Gnoni, A.; Brunetti, O.; Longo, V.; Calabrese, A.; Argentiero, A.; Solimando, A.G.; Licchetta, A. Immune System and Bone Microenvironment: Rationale for Targeted Cancer Therapies. Preprints 2019, 2019090026. https://doi.org/10.20944/preprints201909.0026.v1
Gnoni, A.; Brunetti, O.; Longo, V.; Calabrese, A.; Argentiero, A.; Solimando, A.G.; Licchetta, A. Immune System and Bone Microenvironment: Rationale for Targeted Cancer Therapies. Preprints2019, 2019090026. https://doi.org/10.20944/preprints201909.0026.v1
APA Style
Gnoni, A., Brunetti, O., Longo, V., Calabrese, A., Argentiero, A., Solimando, A.G., & Licchetta, A. (2019). Immune System and Bone Microenvironment: Rationale for Targeted Cancer Therapies. Preprints. https://doi.org/10.20944/preprints201909.0026.v1
Chicago/Turabian Style
Gnoni, A., Antonio Giovanni Solimando and Antonella Licchetta. 2019 "Immune System and Bone Microenvironment: Rationale for Targeted Cancer Therapies" Preprints. https://doi.org/10.20944/preprints201909.0026.v1
Abstract
Osteoimmunology was coined about twenty years ago to identify a strict cross talk between bone niche and immune system both in physiological and pathological activities, including cancer. Several molecules are involved in the complex interaction between bone niche, immune and cancer cells. The Receptor Activator ok NF-kB (RANK)/RANK Ligand (RANKL/Osteoprotegerin (OPG) pathway plays a crucial role in bone cells/cancer interactions with subsequently immune system control failure, bone destruction, inhibition of effect and metastasis outcome. The bidirectional cross talk between bone and immune system could became a potential target for anticancer drugs. Several studies evidenced a direct anticancer role with improved survival of bone-targeted therapies such as bisphosphonates and RANKL antagonist Denosumab. Conversely, initial data evidenced a possible anti-bone resorption effect of systemic anticancer drugs through and immunomodulation activity, i.e. new generation antiandrogens (Abiraterone) in prostate cancer. All data could open a future rationale of combined bone, immunologic and targeted therapies in cancer treatment.
Keywords
antiandrogen; bisphosphonates; bone niche; immune system; osteoimmunology; RankL; targeted therapy
Subject
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
,
,
,
